Veteran medtech executive Scott Huennekens is out as CEO of Verb Surgical, the robot-assisted surgery joint venture between Johnson & Johnson (NYSE:JNJ) and Google parent Alphabet (NSDQ:GOOGL), which today installed Kurt Azarbarzin in the corner office.
“I am incredibly honored and excited to have the opportunity to lead Verb,” Azarbarzin said in prepared remarks. “The company has an incredible vision for the future of surgery. I’ve spent time with the technology, and believe it has the potential to transform surgery on a global scale.
“I’ve been exposed to many surgical technologies and trends over the course of my 35 year career and truly believe that robotics and digital are the future of surgery and I see vast potential in what Verb is developing. I’m joining the company to change surgery for the better,” he said.
“Verb is making strong progress and the response from clinicians around the world has been very positive,” added J&J medical devices chairwoman Ashley McEvoy. “We are pleased to have Kurt’s leadership and expertise guiding the platform towards commercialization.”
NeuroPace promotes commercial chief Favet to CEO
NeuroPace today promoted its acting commercial chief, Michael Favet, to replace Frank Fischer as CEO. After 20 years at the helm Fischer was named chairman, the company said.
Hologic promotes Thornal to lead Dx division
Hologic (NSDQ:HOLX) said it moved medical aesthetics president Kevin Thornal to president of its diagnostics unit and promoted medical aesthetics VP Erik Anderso to replace Thornal there.